101
|
Shin J, Kim HJ, Kim DY, Gong G, Cho KJ. WITHDRAWN:Primary Rhabdomyosarcoma of the Breast: A Report of Two Cases and Literature Review. J Pathol Transl Med 2018:jptm.2018.09.14. [PMID: 30286562 DOI: 10.4132/jptm.2018.09.14] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2018] [Accepted: 09/13/2018] [Indexed: 11/17/2022] Open
Abstract
Ahead of Print article withdrawn by publisher.
Collapse
|
102
|
Guido E, Mussa R, Tamponi U, Aihara H, Al Said S, Asner DM, Atmacan H, Aulchenko V, Aushev T, Ayad R, Babu V, Badhrees I, Bakich AM, Bansal V, Behera P, Berger M, Bhardwaj V, Biswal J, Bondar A, Bonvicini G, Bozek A, Bračko M, Browder TE, Červenkov D, Chekelian V, Chen A, Cheon BG, Chilikin K, Cho K, Choi SK, Choi Y, Choudhury S, Cinabro D, Cunliffe S, Di Carlo S, Doležal Z, Eidelman S, Epifanov D, Fast JE, Ferber T, Fulsom BG, Garg R, Gaur V, Gabyshev N, Garmash A, Gelb M, Giri A, Goldenzweig P, Haba J, Hara T, Hayashii H, Hedges MT, Hou WS, Inami K, Inguglia G, Ishikawa A, Itoh R, Iwasaki M, Iwasaki Y, Jacobs WW, Jeon HB, Jia S, Jin Y, Julius T, Kang KH, Karyan G, Kawasaki T, Kiesling C, Kim DY, Kim JB, Kim KT, Kim SH, Kinoshita K, Kodyš P, Korpar S, Kotchetkov D, Križan P, Kroeger R, Krokovny P, Kulasiri R, Kumar R, Kumita T, Kuzmin A, Kwon YJ, Lee IS, Lee SC, Li LK, Li YB, Li Gioi L, Libby J, Liventsev D, Lubej M, Luo T, MacNaughton J, Masuda M, Matsuda T, Matvienko D, Merola M, Miyabayashi K, Miyata H, Mizuk R, Mohanty GB, Moon HK, Mori T, Nakano E, Nakao M, Nanut T, Nath KJ, Nayak M, Niiyama M, Nishida S, Ogawa S, Ono H, Ostrowicz W, Pakhlova G, Pal B, Pardi S, Park CW, Paul S, Pedlar TK, Pestotnik R, Piilonen LE, Popov V, Rostomyan A, Russo G, Sakai Y, Salehi M, Sanuki T, Schneider O, Schnell G, Schwanda C, Seino Y, Shebalin V, Shen CP, Shibata TA, Shiu JG, Shwartz B, Sokolov A, Starič M, Strube JF, Sumihama M, Sumiyoshi T, Takizawa M, Tanida K, Tenchini F, Uchida M, Uglov T, Unno Y, Usov Y, Van Hulse C, Varner G, Vinokurova A, Wang B, Wang CH, Wang MZ, Wang P, Wang XL, Watanabe M, Watanabe Y, Widmann E, Won E, Ye H, Yelton J, Yuan CZ, Yusa Y, Zakharov S, Zhang ZP, Zhilich V, Zhukova V, Zhulanov V. Observation of ϒ(4S)→η^{'}ϒ(1S). PHYSICAL REVIEW LETTERS 2018; 121:062001. [PMID: 30141661 DOI: 10.1103/physrevlett.121.062001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/27/2018] [Revised: 07/11/2018] [Indexed: 06/08/2023]
Abstract
We report the first observation of the hadronic transition ϒ(4S)→η^{'}ϒ(1S), using 496 fb^{-1} data collected at the ϒ(4S) resonance with the Belle detector at the KEKB asymmetric-energy e^{+}e^{-} collider. We reconstruct the η^{'} meson through its decays to ρ^{0}γ and to π^{+}π^{-}η, with η→γγ. We measure B(ϒ(4S)→η^{'}ϒ(1S))=[3.43±0.88(stat)±0.21(syst)]×10^{-5}, with a significance of 5.7σ.
Collapse
|
103
|
Jang TK, Kim DY, Lee SW, Park JY, Suh DS, Kim JH, Kim YM, Kim YT, Nam JH. Trends in treatment during the last stages of life in end-stage gynecologic cancer patients who received active palliative chemotherapy: a comparative analysis of 10-year data in a single institution. BMC Palliat Care 2018; 17:99. [PMID: 30086748 PMCID: PMC6081917 DOI: 10.1186/s12904-018-0348-7] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2017] [Accepted: 07/09/2018] [Indexed: 01/17/2023] Open
Abstract
BACKGROUND Palliative chemotherapy should be used with caution when attempting to alleviate symptoms in patients with end-stage cancer. However, palliative chemotherapy continues to be utilized in cancer patients during their last stages of life. In this study, we analyzed the pattern of chemotherapy administered during the last 6 months of life in patients with end-stage gynecologic cancer who were treated with active palliative chemotherapy for the past 10 years. METHOD We retrospectively analyzed the data for patients with gynecologic cancer who died after undergoing active palliative chemotherapy without receiving hospice management at Asan Medical Center from 2006 to 2015. Patients were divided into two groups: those who died between 2006 and 2010, and those who died between 2011 and 2015. Based on the electronic medical records, the demographic and baseline characteristics of the patients, hospital admission during the last 6 months, invasive procedures, palliative chemotherapy patterns, and the time of the last chemotherapy session were confirmed. RESULTS A total of 193 patients with gynecologic cancer were eligible for this study. 92 patients died during 2006 to 2010, and 101 patients died during 2011 to 2015. The mean frequency of admission during the last 6 months was 5.12 for those who died in 2006-2010 and 6.06 for those who died during 2011-2015 (p = 0.003); similarly, the mean frequency of palliative chemotherapy during the last 6 months was 3.84 (2006-2010) vs. 4.93 times (2011-2015; p < 0.001). The proportion of patients undergoing invasive procedures during the last 3 months was 41.3% (2005-2010) vs. 56.4% (2011-2015; p = 0.044). CONCLUSIONS The frequency of palliative chemotherapy and the rate of invasive procedures have increased in patients with end-stage gynecologic cancer who were treated aggressively without hospice management over 2011-2015 when compared to 2006-2010, along with an increase in the mean frequency of admission during the last 6 months at our institution. Gynecologic oncologists need to evaluate whether active palliative chemotherapy is beneficial to patients at the end-of-life stage, and if not helpful, should communicate with the patients and caregivers about when the palliative chemotherapy should be discontinued.
Collapse
|
104
|
Yelton J, Adachi I, Ahn JK, Aihara H, Al Said S, Asner DM, Atmacan H, Aushev T, Ayad R, Babu V, Badhrees I, Bahinipati S, Bakich AM, Bansal V, Beleño C, Berger M, Bhardwaj V, Bhuyan B, Bilka T, Biswal J, Bondar A, Bonvicini G, Bozek A, Bračko M, Browder TE, Červenkov D, Chekelian V, Chen A, Cheon BG, Chilikin K, Cho K, Choi SK, Choi Y, Choudhury S, Cinabro D, Cunliffe S, Czank T, Dash N, Di Carlo S, Doležal Z, Dong TV, Drásal Z, Eidelman S, Epifanov D, Fast JE, Fulsom BG, Garg R, Gaur V, Gabyshev N, Garmash A, Gelb M, Giri A, Goldenzweig P, Greenwald D, Guido E, Haba J, Hayasaka K, Hayashii H, Hirose S, Hou WS, Inami K, Inguglia G, Ishikawa A, Itoh R, Iwasaki M, Iwasaki Y, Jacobs WW, Jeon HB, Jia S, Jin Y, Joo KK, Julius T, Kaliyar AB, Kang KH, Karyan G, Kato Y, Kiesling C, Kim DY, Kim JB, Kim KT, Kim SH, Kinoshita K, Kodyš P, Korpar S, Kotchetkov D, Križan P, Kroeger R, Krokovny P, Kuhr T, Kumar R, Kuzmin A, Kwon YJ, Lange JS, Lee IS, Lee SC, Li LK, Li YB, Li Gioi L, Libby J, Liventsev D, Lubej M, Luo T, Masuda M, Matsuda T, Matvienko D, McNeil JT, Merola M, Miyabayashi K, Miyata H, Mizuk R, Mohanty GB, Moon HK, Mori T, Mussa R, Nakano E, Nakao M, Nanut T, Nath KJ, Natkaniec Z, Niiyama M, Nisar NK, Nishida S, Ono H, Pakhlov P, Pakhlova G, Pal B, Pardi S, Park H, Paul S, Pedlar TK, Pestotnik R, Piilonen LE, Popov V, Ritter M, Russo G, Sahoo D, Sakai Y, Sandilya S, Santelj L, Sanuki T, Savinov V, Schneider O, Schnell G, Schwanda C, Seino Y, Senyo K, Sevior ME, Shebalin V, Shen CP, Shibata TA, Shiu JG, Shwartz B, Simon F, Sokolov A, Solovieva E, Starič M, Strube JF, Sumihama M, Sumiyoshi T, Suzuki K, Takizawa M, Tamponi U, Tanida K, Tao Y, Tenchini F, Uchida M, Uglov T, Uno S, Urquijo P, Usov Y, Vahsen SE, Van Hulse C, Varner G, Vorobyev V, Vossen A, Wang B, Wang CH, Wang MZ, Wang P, Wang XL, Watanabe M, Watanuki S, Widmann E, Won E, Ye H, Yuan CZ, Yusa Y, Zakharov S, Zhang ZP, Zhilich V, Zhukova V, Zhulanov V. Observation of an Excited Ω^{-} Baryon. PHYSICAL REVIEW LETTERS 2018; 121:052003. [PMID: 30118260 DOI: 10.1103/physrevlett.121.052003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/23/2018] [Indexed: 06/08/2023]
Abstract
Using data recorded with the Belle detector, we observe a new excited hyperon, an Ω^{*-} candidate decaying into Ξ^{0}K^{-} and Ξ^{-}K_{S}^{0} with a mass of 2012.4±0.7(stat)±0.6(syst) MeV/c^{2} and a width of Γ=6.4_{-2.0}^{+2.5}(stat)±1.6(syst) MeV. The Ω^{*-} is seen primarily in ϒ(1S),ϒ(2S), and ϒ(3S) decays.
Collapse
|
105
|
Park H, Kim HS, Hong YJ, Min JJ, Kim HB, Kim M, Jeong HK, Lim KS, Kim JH, Kim MC, Sim DS, Kim JH, Kim DY, Ahn YK, Jeong MH. P3710Evaluation of treatment with fimasartan in animal myocardial infarction model using cardiac positron emission tomography with [18F]FPTP. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p3710] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
106
|
Baek YS, Kim DY, Park JH, Yoon GS, Choi SH, Ko KY, Kwon SW, Park SD, Shin SH, Woo SI, Kim DH, Kwan J. P6619Long-term impact of metabolic syndrome management on mortality in patients with atrial fibrillation. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p6619] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
107
|
Baek YS, Kim DY, Park JH, Yoon GS, Choi SH, Ko KY, Kwon SW, Park SD, Shin SH, Woo SI, Kim DH, Kwan J. P981Long-term clinical impact of sinus rhythm restoration in atrial fibrillation patients with heart failure with mid-ranged ejection fraction. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy564.p981] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
108
|
Han E, Lee YH, Kim BK, Park JY, Kim DY, Ahn SH, Lee BW, Kang ES, Cha BS, Han KH, Kim SU. Sarcopenia is associated with the risk of significant liver fibrosis in metabolically unhealthy subjects with chronic hepatitis B. Aliment Pharmacol Ther 2018; 48:300-312. [PMID: 29920701 DOI: 10.1111/apt.14843] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/13/2017] [Revised: 11/02/2017] [Accepted: 05/20/2018] [Indexed: 12/23/2022]
Abstract
BACKGROUND Sarcopenia is significantly associated with the degree of liver fibrosis. This study investigated the influence of sarcopenia on liver fibrosis in individuals with chronic hepatitis B. METHODS Data from the Korean National Health and Nutrition Examination Surveys 2008-2011 were analysed. The sarcopenia index (total appendicular skeletal muscle mass [kg]/body mass index [kg/m2 ]) was calculated using dual-energy X-ray absorptiometry. Sarcopenia was defined as the lowest quintile sarcopenia index value (cut-offs: 0.89 for men and 0.58 for women). The fibrotic burden was assessed using the nonalcoholic fatty liver disease fibrosis score and fibrosis-4 index. Significant fibrosis was defined as the highest nonalcoholic fatty liver disease fibrosis score quartile and a fibrosis-4 index ≥2.67. RESULTS Among the 506 respondents with chronic hepatitis B (258 men and 248 women), the nonalcoholic fatty liver disease fibrosis score and fibrosis-4 index identified sarcopenia and significant fibrosis in 126 (24.9%) and 217 (42.9%), respectively. Sarcopenia was significantly associated with significant fibrosis, regardless of the fibrosis prediction model used (all P < 0.05). When the study population was stratified according to metabolic factors, sarcopenia was specifically associated with an increased risk of significant fibrosis among subgroups with obesity, insulin resistance, metabolic syndrome and liver steatosis (odds ratio 2.37-3.57; all P < 0.05). An independent association between sarcopenia and significant fibrosis was identified after adjusting for other confounders (odds ratio 2.67-3.62 by the nonalcoholic fatty liver disease fibrosis score and 2.04-2.62 by the fibrosis-4 index; all P < 0.05). CONCLUSIONS Sarcopenia is associated with significant fibrosis in subjects with chronic hepatitis B, specifically those with obesity, insulin resistance, metabolic syndrome and liver steatosis.
Collapse
|
109
|
Sibidanov A, Varvell KE, Adachi I, Aihara H, Al Said S, Asner DM, Aushev T, Ayad R, Babu V, Badhrees I, Bahinipati S, Bakich AM, Bansal V, Barberio E, Behera P, Bhuyan B, Biswal J, Bozek A, Bračko M, Browder TE, Červenkov D, Chang P, Chekelian V, Chen A, Cheon BG, Chilikin K, Cho K, Choi SK, Choi Y, Cinabro D, Czank T, Dash N, Di Carlo S, Doležal Z, Drásal Z, Dutta D, Eidelman S, Epifanov D, Fast JE, Ferber T, Fulsom BG, Gaur V, Gabyshev N, Garmash A, Goldenzweig P, Greenwald D, Guan Y, Guido E, Haba J, Hayasaka K, Hayashii H, Hedges MT, Hirose S, Hou WS, Hsu CL, Iijima T, Inami K, Inguglia G, Ishikawa A, Itoh R, Iwasaki M, Iwasaki Y, Jacobs WW, Jaegle I, Jeon HB, Jin Y, Joo KK, Julius T, Kahn J, Kaliyar AB, Kang KH, Karyan G, Kawasaki T, Kiesling C, Kim DY, Kim JB, Kim SH, Kim YJ, Kinoshita K, Kodyš P, Korpar S, Kotchetkov D, Križan P, Krokovny P, Kuhr T, Kulasiri R, Kumar R, Kuzmin A, Kwon YJ, Lange JS, Lee IS, Li CH, Li L, Li Gioi L, Libby J, Liventsev D, Lubej M, Luo T, Masuda M, Matsuda T, Merola M, Miyabayashi K, Miyata H, Mizuk R, Mohanty GB, Moon HK, Mori T, Mussa R, Nakano E, Nakao M, Nanut T, Nath KJ, Natkaniec Z, Nayak M, Niiyama M, Nisar NK, Nishida S, Ogawa S, Okuno S, Ono H, Pakhlov P, Pakhlova G, Pal B, Park CS, Park CW, Park H, Paul S, Pedlar TK, Pestotnik R, Piilonen LE, Ritter M, Rostomyan A, Rozanska M, Sakai Y, Salehi M, Sandilya S, Sato Y, Savinov V, Schneider O, Schnell G, Schwanda C, Seino Y, Senyo K, Sevior ME, Shebalin V, Shen CP, Shibata TA, Shiu JG, Simon F, Sokolov A, Solovieva E, Starič M, Strube JF, Stypula J, Sumihama M, Sumisawa K, Sumiyoshi T, Takizawa M, Tamponi U, Tanida K, Tenchini F, Trabelsi K, Uchida M, Uehara S, Uglov T, Unno Y, Uno S, Urquijo P, Van Hulse C, Varner G, Vorobyev V, Wang CH, Wang MZ, Wang P, Watanabe M, Watanuki S, Widmann E, Won E, Yamashita Y, Ye H, Yelton J, Yuan CZ, Yusa Y, Zhang ZP, Zhilich V, Zhukova V, Zhulanov V, Zupanc A. Search for B^{-}→μ^{-}ν[over ¯]_{μ} Decays at the Belle Experiment. PHYSICAL REVIEW LETTERS 2018; 121:031801. [PMID: 30085771 DOI: 10.1103/physrevlett.121.031801] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/12/2017] [Revised: 05/01/2018] [Indexed: 06/08/2023]
Abstract
We report the results of a search for the rare, purely leptonic decay B^{-}→μ^{-}ν[over ¯]_{μ} performed with a 711 fb^{-1} data sample that contains 772×10^{6} BB[over ¯] pairs, collected near the ϒ(4S) resonance with the Belle detector at the KEKB asymmetric-energy e^{+}e^{-} collider. The signal events are selected based on the presence of a high momentum muon and the topology of the rest of the event showing properties of a generic B-meson decay, as well as the missing energy and momentum being consistent with the hypothesis of a neutrino from the signal decay. We find a 2.4 standard deviation excess above background including systematic uncertainties, which corresponds to a branching fraction of B(B^{-}→μ^{-}ν[over ¯]_{μ})=(6.46±2.22±1.60)×10^{-7} or a frequentist 90% confidence level interval on the B^{-}→μ^{-}ν[over ¯]_{μ} branching fraction of [2.9,10.7]×10^{-7}.
Collapse
|
110
|
Colburn A, Wanninayake N, Kim DY, Bhattacharyya D. Cellulose-graphene quantum dot composite membranes using ionic liquid. J Memb Sci 2018; 556:293-302. [PMID: 32095034 PMCID: PMC7039517 DOI: 10.1016/j.memsci.2018.04.009] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Selective separation of small molecules by membranes is inhibited by the performance gap between nanofiltration and ultrafiltration membranes. In this work, a membrane that can efficiently remove small molecules (> 300 Da) was created by incorporating graphene oxide quantum dots (GQDs) into a cellulose membrane using an ionic liquid (1-ethyl-3-methylimidazolium acetate). Incorporation of GQD into cellulose membranes using an ionic liquid brings several advantages over traditional mixed matrix membranes: 1) GQDs are abundant in peripheral hydroxyl and carboxyl groups, thus GQDs have strong binding with cellulose through hydrogen bonding and forms a stable composite membrane. 2) Negative surface charge of GQDs helps prevent aggregation. 3) The size (5 nm) of GQD is smaller than most nanoparticles used in membranes, allowing for interesting pore forming properties. GQD-cellulose membranes were prepared by non-solvent induced phase separation in water. It was determined that about 45% of GQDs are incorporated from solution to membrane. GQDs were determined to be located on the membrane surface, giving the membrane negative surface charge and improved hydrophilicity. GQDs showed no leaching after convective flow through the membrane. Impact of GQD on membrane permeability and rejection was studied through convective flow experiments, and through longer term permeability studies.
Collapse
|
111
|
Chon YE, Jung KS, Kim MJ, Choi JY, An C, Park JY, Ahn SH, Kim BK, Kim SU, Park H, Hwang SK, Rim KS, Han KH, Kim DY. Predictors of failure to detect early hepatocellular carcinoma in patients with chronic hepatitis B who received regular surveillance. Aliment Pharmacol Ther 2018; 47:1201-1212. [PMID: 29492988 DOI: 10.1111/apt.14578] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/04/2017] [Revised: 09/28/2017] [Accepted: 01/30/2018] [Indexed: 12/14/2022]
Abstract
BACKGROUND A proportion of chronic hepatitis B (CHB) patients are diagnosed with advanced hepatocellular carcinoma (HCC) despite regular surveillance. AIMS To determine predictors for HCC detection failure in CHB patients who underwent regular surveillance. METHODS CHB patients with well-preserved liver function, who underwent ultrasonography and alpha-foetoprotein (AFP) analysis every 6 months, were enrolled. Cox regression analysis was used to identify predictors for detection failure, defined as HCC initially diagnosed at Barcelona Clinic Liver Cancer (BCLC) stage B or C. RESULTS Of the 4590 CHB patients (mean age, 52.1 years; men, 61.6%), 169 patients were diagnosed with HCC (3.68%) and 35 (20.7%) HCC patients were initially diagnosed with HCC BCLC stage B or C. The cumulative incidence of HCC detection failure was 0.2% at year 1 and 1.3% at year 5. Multivariate analyses indicated that cirrhosis (hazard ratio [HR], 3.078; 95% CI, 1.389-6.821; P = 0.006), AFP levels ≥9 ng/mL (HR, 5.235; 95% CI, 2.307-11.957; P = 0.010), and diabetes mellitus (HR, 3.336; 95% CI, 1.341-8.296; P = 0.010) were independent predictors of HCC detection failure. Another model that incorporated liver stiffness (LS) values identified LS values ≥11.7 kPa (HR, 11.045; 95% CI, 2.066-59.037; P = 0.005) and AFP levels ≥9 ng/mL (HR, 4.802; 95% CI, 1.613-14.297; P = 0.005) as predictors of detection failure. CONCLUSIONS In CHB patients undergoing regular surveillance with ultrasonography and alpha-foetoprotein (AFP) analysis every 6 months, the HCC detection failure rate was not high (0.8% per person; 0.1% per test). However, careful attention should be paid in patients with advanced liver fibrosis (clinical cirrhosis or LS value >11.7 kPa), high AFP levels, or diabetes mellitus, who are prone to surveillance failure.
Collapse
|
112
|
Kim JH, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT, Nam JH. The efficacy of sentinel lymph node mapping with indocyanine green in cervical cancer. World J Surg Oncol 2018. [PMID: 29523141 PMCID: PMC5845382 DOI: 10.1186/s12957-018-1341-6] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Background Lymph node metastasis is a significant predictive factor for disease recurrence and survival in cervical cancer patients. Given the importance of lymph node metastasis, it is imperative that patients harboring metastasis are identified and can undergo appropriate treatment. Sentinel lymph node (SLN) mapping has drawn attention as a lymph node mapping technique. We evaluated the feasibility and efficacy of (SLN) mapping using indocyanine green (ICG) in cervical cancer. Methods We performed a single-center, retrospective study of 103 surgically treated cervical cancer patients who underwent SLN mapping. After using ICG to detect SLN during surgery, we removed the SLNs followed by laparoscopic or robotic-assisted radical surgery and bilateral pelvic lymphadenectomy. Results Stage IB1 was the most common (61.17%). At least one SLN was detected in all cases. Eighty-eight patients (85.44%) had bilateral pelvic SLNs. The mean number of SLN per patient was 2.34. The side-specific sensitivity was 71.43%, the specificity was 100%, the negative predictive value (NPV) was 93.98%, and the false negative rate (FNR) was 28.57%. In cases of tumors smaller than 2 cm with negative lymph node metastasis on imaging, the study revealed a side-specific sensitivity of 100%, a specificity of 100%, a NPV of 100%, and a FNR of 0%. Large tumor size (≥ 4 cm), a previous history of a loop electrosurgical excision procedure (LEEP), depth of invasion (≥ 50%), the microscopic parametrial (PM) invasion, and vaginal extension were significantly associated with the false-negative detection of SLN. Moreover, the microscopic PM invasion was the only risk factor of the false-negative detection of SLN in multivariate analysis. Conclusion SLN mapping with ICG in cervical cancer is feasible and has high detection rate. The sensitivity of 100% was high enough to perform SLN biopsy alone in an early stage in which the tumor is less than 2 cm, with no lymphadenopathy on image examination. However, for large or invasive tumors, we would have to be cautious about performing SLN biopsy alone. Trial registration Retrospectively registered 2017-0600.
Collapse
|
113
|
Lee SS, Lee CM, Kim TH, Kim JJ, Lee JM, Kim HJ, Ha CY, Kim HJ, Jung WT, Lee OJ, Kim DY. Frequency and risk factors of drug-induced liver injury during treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2018; 20:800-5. [PMID: 27155184 DOI: 10.5588/ijtld.15.0668] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
OBJECTIVES To investigate the risk factors for drug-induced liver injury (DILI) during the treatment of multidrug-resistant tuberculosis (MDR-TB) and to compare the frequency of DILI in patients with and those without chronic liver disease (CLD). SETTING This was a retrospective observational cohort study including 299 consecutive patients who started MDR-TB treatment from January 2009 to December 2013. DESIGN Of the 299 patients, 35 had alcoholic liver disease (ALD group), 16 had hepatitis B virus infection (HBV group) and 11 had hepatitis C virus infection (HCV group). The remaining 237 patients without CLD were selected as the control group. RESULTS DILI occurred in 29 (9.7%) patients. The frequency of DILI was significantly higher in the ALD (17.1%, P = 0.038), HBV (31.3%, P = 0.005) and HCV groups (27.3%, P = 0.037) than in the control group (6.3%). Among all patients taken together, having HBV and HCV infection were independent risk factors for the occurrence of DILI during MDR-TB treatment. CONCLUSION DILI during MDR-TB treatment occurred more frequently in patients with CLD due to ALD, HBV and HCV infection than in those without CLD.
Collapse
|
114
|
Lee SW, Park SM, Kim YM, Kim YS, Choi EK, Kim DY, Kim JH, Nam JH, Kim YT. Radiation therapy is a treatment to be considered for recurrent epithelial ovarian cancer after chemotherapy. TUMORI JOURNAL 2018; 97:590-5. [DOI: 10.1177/030089161109700509] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Aims and background Radiation therapy provides a safe and effective alternative treatment option for recurrent epithelial ovarian cancer, although it has not been a treatment of choice. We evaluated the efficacy and toxicity of radiation therapy for recurrent epithelial ovarian cancer after chemotherapy according to the disease status. Methods This was a retrospective study of 38 patients with recurrent epithelial ovarian cancer treated with radiation therapy at the Asan Medical Center, Seoul, Korea, between January 1997 and December 2007. We analyzed their clinical characteristics and the outcome of radiation therapy. Results Thirty-eight patients were treated with radiation therapy. Their median age was 51.5 years. Most patients were FIGO stage III (27/38) with serous adenocarcinoma (26/38). All patients had received at least one regimen of platinum-based chemotherapy; 24 patients were sensitive to the first chemotherapy and the others were resistant. Lymph node and abdominopelvic wall were the most common sites of radiation therapy. The response rate was 65.0% (16 complete remissions and 10 partial remissions), and the median regression rate was 78.8% (range, −66.6 to 100.0). Median progression-free survival was 7.2 months (range, 1.0–66.6). In 28 patients who had a solitary relapsed site from the radiographic finding at the time of radiation therapy, it was 10.7 months (range, 1.8–66.6). Neither hematologic nor intestinal toxicity of grade 3–4 was observed. Prognostic factors were sensitivity to platinum and the site treated with radiation therapy. Conclusions Radiation therapy is a treatment that should be considered for recurrent epithelial ovarian cancer, especially in good responders to platinum or patients with solitary relapsed lesions.
Collapse
|
115
|
Ha SM, Hwang S, Song GW, Ahn CS, Moon DB, Ha TY, Jung DH, Park GC, Kim KH, Kim DY, Namgung J, Kang WH, Kim SH, Jwa E, Kwon JH, Cho HD, Jung YK, Kang SH, Lee SG. Successful introduction of Model for End-stage Liver Disease scoring in deceased donor liver transplantation in Korea: analysis of first 1 year experience at a high-volume transplantation center. Ann Hepatobiliary Pancreat Surg 2017; 21:199-204. [PMID: 29264582 PMCID: PMC5736739 DOI: 10.14701/ahbps.2017.21.4.199] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/01/2017] [Revised: 11/10/2017] [Accepted: 11/15/2017] [Indexed: 12/13/2022] Open
Abstract
Backgrounds/Aims Model for End-stage Liver Disease (MELD) score was adopted in June 2016 in Korea. Methods We analyzed changes in volumes and outcomes of deceased donor liver transplantation (DDLT) for 1 year before and after introduction of MELD scoring at Asan Medical Center. Results There were 64 cases of DDLT in 1 year before MELD introduction and 106 in 1 year after MELD introduction, an increase of 65%. The volume of DDLTs abruptly increased during first 3 months, but then returned to its usual level before MELD introduction, which indicated 3-month depletion of accumulated recipient pool with high MELD scores. The number of pediatric DDLT cases increased from 3 before MELD introduction to 11 after it, making up 21.4% and 47.8% of all cases of pediatric liver transplantation, respectively. The number of cases of retransplanted DDLTs increased from 4 to 27, representing 6.3% and 25.5% of all DDLT cases, respectively. The number of status 1 DDLT cases increased from 5 to 12, being 7.8% and 11.3% of all cases. Patient survival outcomes were similar before and after MELD introduction. Conclusions The number of DDLTs temporarily increased after adoption of MELD scoring due to accumulated recipient pool with high MELD scores. The numbers of retransplanted and pediatric DDLT cases significantly increased. Patient survival in adult and pediatric DDLT was comparable before and after adoption of MELD scoring. These results imply that Korean MELD score-based allocation system was successfully established within its first year.
Collapse
|
116
|
Horiguchi T, Ishikawa A, Yamamoto H, Adachi I, Aihara H, Al Said S, Asner DM, Aulchenko V, Aushev T, Ayad R, Babu V, Badhrees I, Bakich AM, Bansal V, Behera P, Bhardwaj V, Bhuyan B, Biswal J, Bobrov A, Bonvicini G, Bozek A, Bračko M, Browder TE, Červenkov D, Chekelian V, Chen A, Cheon BG, Chilikin K, Cho K, Choi Y, Cinabro D, Czank T, Dash N, Di Carlo S, Doležal Z, Drásal Z, Dutta D, Eidelman S, Epifanov D, Farhat H, Fast JE, Ferber T, Fulsom BG, Gaur V, Gabyshev N, Garmash A, Gelb M, Gillard R, Goldenzweig P, Golob B, Guan Y, Guido E, Haba J, Hara T, Hayasaka K, Hayashii H, Hedges MT, Higuchi T, Hirose S, Hou WS, Iijima T, Inami K, Inguglia G, Itoh R, Iwasaki Y, Jacobs WW, Jaegle I, Jeon HB, Jia S, Jin Y, Joffe D, Joo KK, Julius T, Kang KH, Kawasaki T, Kim DY, Kim JB, Kim KT, Kim MJ, Kim SH, Kim YJ, Kinoshita K, Kodyš P, Korpar S, Kotchetkov D, Križan P, Krokovny P, Kuhr T, Kulasiri R, Kumar R, Kumita T, Kuzmin A, Kwon YJ, Lange JS, Li CH, Li L, Li Gioi L, Libby J, Liventsev D, Lubej M, Luo T, Masuda M, Matsuda T, Matvienko D, Merola M, Miyabayashi K, Miyata H, Mizuk R, Mohanty GB, Mohanty S, Moon HK, Mori T, Mussa R, Nakano E, Nakao M, Nanut T, Nath KJ, Natkaniec Z, Nayak M, Nisar NK, Nishida S, Ogawa S, Okuno S, Ono H, Pakhlov P, Pakhlova G, Pal B, Pardi S, Park CS, Park H, Paul S, Pedlar TK, Pestotnik R, Piilonen LE, Prasanth K, Pulvermacher C, Rauch J, Rostomyan A, Sakai Y, Sandilya S, Santelj L, Savinov V, Schneider O, Schnell G, Schwanda C, Schwartz AJ, Seino Y, Senyo K, Seong IS, Sevior ME, Shebalin V, Shen CP, Shibata TA, Shiu JG, Simon F, Sokolov A, Solovieva E, Starič M, Strube JF, Sumisawa K, Sumiyoshi T, Takizawa M, Tamponi U, Tanida K, Tenchini F, Trabelsi K, Uchida M, Uglov T, Unno Y, Uno S, Urquijo P, Ushiroda Y, Usov Y, Van Hulse C, Varner G, Vinokurova A, Vorobyev V, Vossen A, Wang CH, Wang MZ, Wang P, Watanabe Y, Watanuki S, Weber T, Widmann E, Won E, Yamashita Y, Ye H, Zhang ZP, Zhilich V, Zhukova V, Zhulanov V, Zupanc A. Evidence for Isospin Violation and Measurement of CP Asymmetries in B→K^{*}(892)γ. PHYSICAL REVIEW LETTERS 2017; 119:191802. [PMID: 29219495 DOI: 10.1103/physrevlett.119.191802] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/29/2017] [Indexed: 06/07/2023]
Abstract
We report the first evidence for isospin violation in B→K^{*}γ and the first measurement of the difference of CP asymmetries between B^{+}→K^{*+}γ and B^{0}→K^{*0}γ. This analysis is based on the data sample containing 772×10^{6}BB[over ¯] pairs that was collected with the Belle detector at the KEKB energy-asymmetric e^{+}e^{-} collider. We find evidence for the isospin violation with a significance of 3.1σ, Δ_{0+}=[+6.2±1.5(stat)±0.6(syst)±1.2(f_{+-}/f_{00})]%, where the third uncertainty is due to the uncertainty on the fraction of B^{+}B^{-} to B^{0}B[over ¯]^{0} production in ϒ(4S) decays. The measured value is consistent with predictions of the standard model. The result for the difference of CP asymmetries is ΔA_{CP}=[+2.4±2.8(stat)±0.5(syst)]%, consistent with zero. The measured branching fractions and CP asymmetries for charged and neutral B meson decays are the most precise to date. We also calculate the ratio of branching fractions of B^{0}→K^{*0}γ to B_{s}^{0}→ϕγ.
Collapse
|
117
|
Dash N, Bahinipati S, Bhardwaj V, Trabelsi K, Adachi I, Aihara H, Al Said S, Asner DM, Aulchenko V, Aushev T, Ayad R, Babu V, Badhrees I, Bakich AM, Bansal V, Barberio E, Bhuyan B, Biswal J, Bobrov A, Bondar A, Bonvicini G, Bozek A, Bračko M, Breibeck F, Browder TE, Červenkov D, Chang MC, Chekelian V, Chen A, Cheon BG, Chilikin K, Cho K, Choi Y, Cinabro D, Di Carlo S, Doležal Z, Drásal Z, Dutta D, Eidelman S, Epifanov D, Farhat H, Fast JE, Ferber T, Fulsom BG, Gaur V, Gabyshev N, Garmash A, Gillard R, Goldenzweig P, Haba J, Hara T, Hayasaka K, Hayashii H, Hedges MT, Hou WS, Iijima T, Inami K, Ishikawa A, Itoh R, Iwasaki Y, Jacobs WW, Jaegle I, Jeon HB, Jin Y, Joffe D, Joo KK, Julius T, Kahn J, Kaliyar AB, Karyan G, Katrenko P, Kawasaki T, Kiesling C, Kim DY, Kim HJ, Kim JB, Kim KT, Kim MJ, Kim SH, Kim YJ, Kinoshita K, Kodyš P, Korpar S, Kotchetkov D, Križan P, Krokovny P, Kuhr T, Kulasiri R, Kumar R, Kumita T, Kuzmin A, Kwon YJ, Lange JS, Lee IS, Li CH, Li L, Li Y, Li Gioi L, Libby J, Liventsev D, Lubej M, Luo T, Masuda M, Matvienko D, Merola M, Miyabayashi K, Miyata H, Mizuk R, Mohanty GB, Mohanty S, Moon HK, Mori T, Mussa R, Nakano E, Nakao M, Nanut T, Nath KJ, Natkaniec Z, Nayak M, Niiyama M, Nisar NK, Nishida S, Ogawa S, Okuno S, Ono H, Pakhlov P, Pakhlova G, Pal B, Pardi S, Park CS, Park H, Paul S, Pedlar TK, Pesántez L, Pestotnik R, Piilonen LE, Prasanth K, Ritter M, Rostomyan A, Sahoo H, Sakai Y, Sandilya S, Santelj L, Sanuki T, Sato Y, Savinov V, Schneider O, Schnell G, Schwanda C, Schwartz AJ, Seino Y, Senyo K, Sevior ME, Shebalin V, Shen CP, Shibata TA, Shiu JG, Shwartz B, Simon F, Sokolov A, Solovieva E, Starič M, Strube JF, Stypula J, Sumisawa K, Sumiyoshi T, Takizawa M, Tamponi U, Tanida K, Tenchini F, Uchida M, Uglov T, Unno Y, Uno S, Urquijo P, Usov Y, Van Hulse C, Varner G, Vorobyev V, Vossen A, Waheed E, Wang CH, Wang MZ, Wang P, Watanabe M, Watanabe Y, Widmann E, Williams KM, Won E, Yamashita Y, Ye H, Yelton J, Yook Y, Yuan CZ, Yusa Y, Zhang ZP, Zhilich V, Zhukova V, Zhulanov V, Zupanc A. Search for CP Violation and Measurement of the Branching Fraction in the Decay D^{0}→K_{S}^{0}K_{S}^{0}. PHYSICAL REVIEW LETTERS 2017; 119:171801. [PMID: 29219447 DOI: 10.1103/physrevlett.119.171801] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/22/2017] [Indexed: 06/07/2023]
Abstract
We report a study of the decay D^{0}→K_{S}^{0}K_{S}^{0} using 921 fb^{-1} of data collected at or near the ϒ(4S) and ϒ(5S) resonances with the Belle detector at the KEKB asymmetric energy e^{+}e^{-} collider. The measured time-integrated CP asymmetry is A_{CP}(D^{0}→K_{S}^{0}K_{S}^{0})=(-0.02±1.53±0.02±0.17)%, and the branching fraction is B(D^{0}→K_{S}^{0}K_{S}^{0})=(1.321±0.023±0.036±0.044)×10^{-4}, where the first uncertainty is statistical, the second is systematic, and the third is due to the normalization mode (D^{0}→K_{S}^{0}π^{0}). These results are significantly more precise than previous measurements available for this mode. The A_{CP} measurement is consistent with the standard model expectation.
Collapse
|
118
|
Park IW, Kim DY, Bae JS, Na MK. Secondary metabolites with anti-platelet aggregation activity from the insect Tenebrio molitor. Am J Transl Res 2017. [DOI: 10.1055/s-0037-1608123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
119
|
Tang CSM, Gui H, Kapoor A, Kim JH, Luzón-Toro B, Pelet A, Burzynski G, Lantieri F, So MT, Berrios C, Shin HD, Fernández RM, Le TL, Verheij JBGM, Matera I, Cherny SS, Nandakumar P, Cheong HS, Antiñolo G, Amiel J, Seo JM, Kim DY, Oh JT, Lyonnet S, Borrego S, Ceccherini I, Hofstra RMW, Chakravarti A, Kim HY, Sham PC, Tam PKH, Garcia-Barceló MM. Trans-ethnic meta-analysis of genome-wide association studies for Hirschsprung disease. Hum Mol Genet 2017; 25:5265-5275. [PMID: 27702942 DOI: 10.1093/hmg/ddw333] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2016] [Accepted: 09/28/2016] [Indexed: 02/04/2023] Open
Abstract
Hirschsprung disease (HSCR) is the most common cause of neonatal intestinal obstruction. It is characterized by the absence of ganglia in the nerve plexuses of the lower gastrointestinal tract. So far, three common disease-susceptibility variants at the RET, SEMA3 and NRG1 loci have been detected through genome-wide association studies (GWAS) in Europeans and Asians to understand its genetic etiologies. Here we present a trans-ethnic meta-analysis of 507 HSCR cases and 1191 controls, combining all published GWAS results on HSCR to fine-map these loci and narrow down the putatively causal variants to 99% credible sets. We also demonstrate that the effects of RET and NRG1 are universal across European and Asian ancestries. In contrast, we detected a European-specific association of a low-frequency variant, rs80227144, in SEMA3 [odds ratio (OR) = 5.2, P = 4.7 × 10-10]. Conditional analyses on the lead SNPs revealed a secondary association signal, corresponding to an Asian-specific, low-frequency missense variant encoding RET p.Asp489Asn (rs9282834, conditional OR = 20.3, conditional P = 4.1 × 10-14). When in trans with the RET intron 1 enhancer risk allele, rs9282834 increases the risk of HSCR from 1.1 to 26.7. Overall, our study provides further insights into the genetic architecture of HSCR and has profound implications for future study designs.
Collapse
|
120
|
Kim JH, Jung SM, Shin JG, Cheong HS, Seo JM, Kim DY, Oh JT, Kim HY, Jung K, Shin HD. Potential association between ITPKC genetic variations and Hirschsprung disease. Mol Biol Rep 2017; 44:307-313. [PMID: 28664405 DOI: 10.1007/s11033-017-4111-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2016] [Accepted: 06/24/2017] [Indexed: 02/03/2023]
Abstract
Hirschsprung disease (HSCR) is a congenital and complex disorder characterized by intestinal obstruction due to the absence of enteric neurons along variable lengths of the hindgut. Our recent genome-wide association study (GWAS) has revealed regional associations with HSCR at several loci of inositol-trisphosphate 3-kinase C (ITPKC). For fine mapping, we additionally selected and genotyped a total of 12 single nucleotide polymorphisms (SNPs) of ITPKC in 187 HSCR patients and 283 unaffected controls, and performed a further combined imputation analysis based on genotype data from this second stage of fine mapping and our previous GWAS stage, totaling 902 subjects (187 HSCR cases and 715 controls). As a result, several SNPs (minimum P = 0.004) and a haplotype (P = 0.02) were found to be significantly associated with HSCR. In further in silico analyses to ascertain the potential functions of the significant variants, the change from the common allele to the rare allele of the highly conserved nonsynonymous rs76785336 showed a difference in mRNA folding structure. In the case of intronic SNPs, rs2607420 with a high consensus value was predicted to be a new splice site. Although this study has limitations (such as lack of functional evaluations, small number of cases, and further need of replication in other cohorts), our findings suggest that genetic variants of ITPKC may have a potential association with HSCR susceptibility and/or developmental diseases related to enteric nervous system development.
Collapse
|
121
|
Jeong WS, Choi JW, Kim DY, Lee JY, Kwon SM. Corrigendum to "Can a surgery-first orthognathic approach reduce the total treatment time?" [Int. J. Oral Maxillofac. Surg. 46 (2017) 473-482]. Int J Oral Maxillofac Surg 2017. [PMID: 28623044 DOI: 10.1016/j.ijom.2017.05.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
122
|
Hirose S, Iijima T, Adachi I, Adamczyk K, Aihara H, Al Said S, Asner DM, Atmacan H, Aulchenko V, Aushev T, Ayad R, Babu V, Badhrees I, Bakich AM, Bansal V, Barberio E, Behera P, Berger M, Bhuyan B, Biswal J, Bondar A, Bonvicini G, Bozek A, Bračko M, Browder TE, Červenkov D, Chang P, Chen A, Cheon BG, Chilikin K, Chistov R, Cho K, Choi Y, Cinabro D, Danilov M, Dash N, Di Carlo S, Dingfelder J, Doležal Z, Drásal Z, Dutta D, Eidelman S, Epifanov D, Farhat H, Fast JE, Ferber T, Fulsom BG, Gaur V, Gabyshev N, Garmash A, Goldenzweig P, Golob B, Greenwald D, Grygier J, Haba J, Hara K, Hasenbusch J, Hayasaka K, Hayashii H, Higuchi T, Hou WS, Hsu CL, Inami K, Inguglia G, Ishikawa A, Itoh R, Iwasaki Y, Jacobs WW, Jaegle I, Jin Y, Joffe D, Joo KK, Julius T, Kato Y, Kawasaki T, Kichimi H, Kiesling C, Kim DY, Kim JB, Kim KT, Kim MJ, Kim SH, Kinoshita K, Kodyš P, Korpar S, Kotchetkov D, Križan P, Krokovny P, Kuhr T, Kulasiri R, Kumar R, Kwon YJ, Lange JS, Li CH, Li L, Li Y, Li Gioi L, Libby J, Liventsev D, Lubej M, Luo T, MacNaughton J, Masuda M, Matsuda T, Matvienko D, Miyabayashi K, Miyake H, Miyata H, Mizuk R, Mohanty GB, Moon HK, Mori T, Mussa R, Nakao M, Nanut T, Nath KJ, Natkaniec Z, Nayak M, Niiyama M, Nisar NK, Nishida S, Ogawa S, Okuno S, Ono H, Onuki Y, Ostrowicz W, Pakhlov P, Pakhlova G, Pal B, Park CW, Park H, Paul S, Pesántez L, Pestotnik R, Piilonen LE, Prasanth K, Ritter M, Rostomyan A, Rozanska M, Sakai Y, Sandilya S, Santelj L, Sanuki T, Sato Y, Savinov V, Schlüter T, Schneider O, Schnell G, Schwanda C, Seino Y, Senyo K, Seon O, Sevior ME, Shebalin V, Shen CP, Shibata TA, Shiu JG, Simon F, Sokolov A, Solovieva E, Starič M, Strube JF, Sumisawa K, Sumiyoshi T, Takizawa M, Tamponi U, Tenchini F, Trabelsi K, Uchida M, Uglov T, Unno Y, Uno S, Urquijo P, Ushiroda Y, Usov Y, Van Hulse C, Varner G, Varvell KE, Vossen A, Wang CH, Wang MZ, Wang P, Watanabe M, Watanabe Y, Widmann E, Won E, Yamashita Y, Ye H, Yelton J, Yuan CZ, Zhang ZP, Zhilich V, Zhulanov V, Zupanc A. Measurement of the τ Lepton Polarization and R(D^{*}) in the Decay B[over ¯]→D^{*}τ^{-}ν[over ¯]_{τ}. PHYSICAL REVIEW LETTERS 2017; 118:211801. [PMID: 28598663 DOI: 10.1103/physrevlett.118.211801] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/01/2016] [Indexed: 06/07/2023]
Abstract
We report the first measurement of the τ lepton polarization P_{τ}(D^{*}) in the decay B[over ¯]→D^{*}τ^{-}ν[over ¯]_{τ} as well as a new measurement of the ratio of the branching fractions R(D^{*})=B(B[over ¯]→D^{*}τ^{-}ν[over ¯]_{τ})/B(B[over ¯]→D^{*}ℓ^{-}ν[over ¯]_{ℓ}), where ℓ^{-} denotes an electron or a muon, and the τ is reconstructed in the modes τ^{-}→π^{-}ν_{τ} and τ^{-}→ρ^{-}ν_{τ}. We use the full data sample of 772×10^{6} BB[over ¯] pairs recorded with the Belle detector at the KEKB electron-positron collider. Our results, P_{τ}(D^{*})=-0.38±0.51(stat)_{-0.16}^{+0.21}(syst) and R(D^{*})=0.270±0.035(stat)_{-0.025}^{+0.028}(syst), are consistent with the theoretical predictions of the standard model.
Collapse
|
123
|
Park JY, Baek MH, Park YH, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT, Nam JH. Impact of beta blocker medication on survival outcome of ovarian cancer: A nationwide population-based cohort study. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.5578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5578 Background: In experimental studies, adrenergic hormones are involved in tumorigenesis of ovarian cancer and its progression. We investigated the impact of beta adrenergic blocker on survival outcome of ovarian cancer since few studies have investigated its relevance. Methods: Data of Korean National Health Insurance Service was analyzed (n = 866). We analyzed the impact of beta blocker on survival outcome of ovarian cancer according to the duration on medication and age groups of patients. Cox proportional hazards regression was used to analyze hazard ratios (HR) for all-cause mortality with 95% confidence intervals (CI) adjusting for confounding factors. Results: Median years of follow-up was 5.98 and 6.71 for non-users and users, respectively. Among the 866 patients, 206 (23.8%) were users and 660 (76.2%) were non-users. In total, there was no survival difference between the 2 groups. But, when patietns were grouped according to the duration of medication, patients with longer duration of medication (≥1 year) showed better survival outcome (adjusted HR 0.305 [95% CI: 0.187-0.500], P < 0.001). Also, beta blocker use in patients with > 60 years showed better survival compared to younger patients (adjusted HR 0.579 [95% CI: 0.408-0.822], P = 0.002). In patients with > 60 years, medication longer than 720 days was associated with better survival outcome (adjusted HR 0.267 [95% CI: 0.140-0.511], P < 0.001). Both selective and non-selective beta blocker showed identical survival benefit in these settings without difference between each other. Conclusions: Beta blocker medication was associated with favorable survival outcome in ovarian cancer, especially when used in older patients and in long term duration.
Collapse
|
124
|
Shim SH, Kim DY, Kim HJ, Lee SW, Park JY, Suh DS, Kim JH, Kim YM, Kim YT, Nam JH. Stratification of risk groups according to survival after recurrence in endometrial cancer patients. Medicine (Baltimore) 2017; 96:e6920. [PMID: 28538383 PMCID: PMC5457863 DOI: 10.1097/md.0000000000006920] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
To identify prognostic factors for overall survival after recurrence (OSr) in endometrioid endometrial cancer (EC) patients and categorize patient subgroups that predict outcomes using these variables.Consecutive patients with recurrent endometrioid EC seen in our institution from 1989 to 2013 were retrospectively reviewed. Cox regression models were used to identify the clinicopathological factors associated with OSr. By summing scores proportionate to the hazard ratio (HR) for each significant variable, we stratified patients into 3 risk groups.Enrolled patients (n = 108) had a median time to recurrence of 15 (range, 3-163) months after initial treatment and a median OSr of 22 (range, 1-207) months. Twenty patients (18.5%) had locoregional recurrence, and 88 (81.5%) distant. One hundred three patients underwent salvage therapy; 51 (47.2%) received chemotherapy only, 22 (20.3%) received radiotherapy either alone or combined with chemotherapy, and 29 (26.9%) underwent salvage cytoreductive surgery. Multivariate regression analysis revealed that time to relapse after initial treatment, cancer antigen-125 level at recurrence, and the number of recurrent lesions were independent predictors of OSr. Incorporating these factors, we stratified patients into low-risk (n = 19), intermediate-risk (n = 43), and high-risk (n = 46) groups. The likelihood of cancer-specific death was higher in both the high-risk (HR = 8.948, 95% confidence interval [CI] = 3.498-22.893, P < .001) and the intermediate-risk (HR = 2.619, 95% CI = 1.002-6.850, P = .05) groups compared with the low-risk group.Incorporating 3 variables, recurrent endometrioid EC patients with a broad spectrum of outcome could be stratified according to OSr. This model may help predict outcomes in recurrent EC patients.
Collapse
|
125
|
Qazi Y, Shaffer D, Kaplan B, Kim DY, Luan FL, Peddi VR, Shihab F, Tomlanovich S, Yilmaz S, McCague K, Patel D, Mulgaonkar S. Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data. Am J Transplant 2017; 17:1358-1369. [PMID: 27775865 DOI: 10.1111/ajt.14090] [Citation(s) in RCA: 59] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2016] [Revised: 09/11/2016] [Accepted: 10/07/2016] [Indexed: 01/25/2023]
Abstract
In this 12-month, multicenter, randomized, open-label, noninferiority study, de novo renal transplant recipients (RTxRs) were randomized (1:1) to receive everolimus plus low-dose tacrolimus (EVR+LTac) or mycophenolate mofetil plus standard-dose Tac (MMF+STac) with induction therapy (basiliximab or rabbit anti-thymocyte globulin). Noninferiority of composite efficacy failure rate (treated biopsy-proven acute rejection [tBPAR]/graft loss/death/loss to follow-up) in EVR+LTac versus MMF+STac was missed by 1.4%, considering the noninferiority margin of 10% (24.6% vs. 20.4%; 4.2% [-3.0, 11.4]). Incidence of tBPAR (19.1% vs. 11.2%; p < 0.05) was significantly higher, while graft loss (1.3% vs. 3.9%; p < 0.05) and composite of graft loss/death/lost to follow-up (6.1% vs. 10.5%, p = 0.05) were significantly lower in EVR+LTac versus MMF+STac groups, respectively. Mean estimated glomerular filtration rate was similar between EVR+LTac and MMF+STac groups (63.1 [22.0] vs. 63.1 [19.5] mL/min/1.73 m2 ) and safety was comparable. In conclusion, EVR+LTac missed noninferiority versus MMF+STac based on the 10% noninferiority margin. Further studies evaluating optimal immunosuppression for improved efficacy will guide appropriate dosing and target levels of EVR and LTac in RTxRs.
Collapse
|